These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32119586)

  • 1. Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
    Tsuda K
    Circulation; 2020 Mar; 141(9):e100-e101. PubMed ID: 32119586
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
    Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Bami K; Gandhi S; Leong-Poi H; Yan AT; Ho E; Zahrani M; Garg V; Zuo F; Teoh H; Quan A; Leiter LA; Gilbert RE; Zinman B; Thorpe KE; Jüni P; Mazer CD; Verma S; Ong G; Connelly KA
    J Am Soc Echocardiogr; 2020 May; 33(5):644-646. PubMed ID: 32199780
    [No Abstract]   [Full Text] [Related]  

  • 4. Empagliflozin does not affect left ventricular diastolic function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
    Rai A; Connelly KA; Verma S; Mazer CD; Teoh H; Ng MY; Roifman I; Quan A; Pourafkari M; Jimenez-Juan L; Ramanan V; Ge Y; Deva DP; Yan AT
    Acta Diabetol; 2022 Apr; 59(4):575-578. PubMed ID: 35061101
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of Empagliflozin on Left Ventricular Strain: Insights From the EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Moses S; Verma S; Mazer CD; Teoh H; Quan A; Jimenez-Juan L; Deva DP; Yan AT; Connelly KA
    JACC Cardiovasc Imaging; 2022 Oct; 15(10):1832-1834. PubMed ID: 36202464
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
    Mason T; Coelho-Filho OR; Verma S; Chowdhury B; Zuo F; Quan A; Thorpe KE; Bonneau C; Teoh H; Gilbert RE; Leiter LA; Jüni P; Zinman B; Jerosch-Herold M; Mazer CD; Yan AT; Connelly KA
    JACC Cardiovasc Imaging; 2021 Jun; 14(6):1164-1173. PubMed ID: 33454272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial.
    Verma S; Mazer CD; Fitchett D; Inzucchi SE; Pfarr E; George JT; Zinman B
    Diabetologia; 2018 Aug; 61(8):1712-1723. PubMed ID: 29777264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
    Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.
    Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V
    Cardiovasc Diabetol; 2017 Oct; 16(1):130. PubMed ID: 29025406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
    J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
    Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute benefits of empagliflozin in type 2 diabetes: a game changer?
    Kumana CR; Tan KCB; Cheung BMY
    Postgrad Med J; 2017 Jul; 93(1101):373-375. PubMed ID: 28433975
    [No Abstract]   [Full Text] [Related]  

  • 15. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
    Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
    Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
    Butler J; Zannad F; Fitchett D; Zinman B; Koitka-Weber A; von Eynatten M; Zwiener I; George J; Brueckmann M; Cheung AK; Wanner C
    Circ Heart Fail; 2019 Jun; 12(6):e005875. PubMed ID: 31163986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton RJ
    Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-REG OUTCOME: The Cardiologist's Point of View.
    Pham SV; Chilton R
    Am J Med; 2017 Jun; 130(6S):S57-S62. PubMed ID: 28526181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study.
    Cohen ND; Gutman SJ; Briganti EM; Taylor AJ
    Intern Med J; 2019 Aug; 49(8):1006-1010. PubMed ID: 30784160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.